Cargando…

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

BACKGROUND: Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. METHODS: Two open-label, phase 2 studies enrolled patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vijayvergia, Namrata, Dasari, Arvind, Deng, Mengying, Litwin, Samuel, Al-Toubah, Taymeyah, Alpaugh, R. Katherine, Dotan, Efrat, Hall, Michael J., Ross, Nicole M., Runyen, Melissa M., Denlinger, Crystal S., Halperin, Daniel M., Cohen, Steven J., Engstrom, Paul F., Strosberg, Jonathan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188798/ https://www.ncbi.nlm.nih.gov/pubmed/32152503 http://dx.doi.org/10.1038/s41416-020-0775-0

Ejemplares similares

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020)

Chemotherapy in Neuroendocrine Tumors
por: Das, Satya, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022)

Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed
por: Vijayvergia, Namrata, et al.
Publicado: (2015)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023)

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms
por: Kaur, Jasmeet, et al.
Publicado: (2023)

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
por: Eads, Jennifer R, et al.
Publicado: (2023)

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation
por: Eng, Cathy, et al.
Publicado: (2021)

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
por: Barros, Milton J., et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
por: Das, Satya, et al.
Publicado: (2021)

Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States
por: Shah, Shrunjal, et al.
Publicado: (2021)

Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on Outcomes in Esophageal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
por: Jain, Rishi, et al.
Publicado: (2020)

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study
por: Vijayvergia, Namrata, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)
por: Mohamed, Amr, et al.
Publicado: (2022)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)
por: Mohamed, Amr, et al.
Publicado: (2022)

Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis
por: Mehrvarz Sarshekeh, Amir, et al.
Publicado: (2017)

Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease
por: Halperin, Reut, et al.
Publicado: (2023)

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Assessing Oncologists’ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data
por: Iyer, Pritish, et al.
Publicado: (2022)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Diagnostic Approach to a Patient With Paraneoplastic Neurological Syndrome
por: Mahta, Ali, et al.
Publicado: (2012)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

THU508 Does Mid-treatment Response To 177Lu-DOTATATE Predict Treatment Outcome In Patients With Neuroendocrine Neoplasms?
por: Halperin, Reut, et al.
Publicado: (2023)

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
por: Zibelman, Matthew, et al.
Publicado: (2023)

Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
por: Das, Satya, et al.
Publicado: (2021)

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
por: Grob, Jean-Jacques, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mcfn82thn00gn8fiu27te6ct2g